Conor Lynch

Has grant

Associate Professor

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach

Open Date: 2020-06-11

Close Date: 2025-05-31

Grant: Close

Local and systemic control of multiple myeloma colonization and growth by MMP-13

Open Date: 2019-03-01

Close Date: 2024-02-28

Grant: Close

Mesenchymal Stem Cell Control of Metastatic Prostate Cancer Cell Evolution and Therapy Resistance in the Bone Microenvironment

Open Date: 2016-10-01

Close Date: 2017-09-01

Grant: Close

Multiscale Modeling of Bone Environment Responses to Metastatic Prostate Cancer

Open Date: 2016-06-08

Close Date: 2021-05-31

Grant: Close

Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma

Open Date: 2015-07-02

Close Date: 2018-06-30

Articles (4)

Understanding dormancy in prostate cancer is challenging because of model availability. In this study, using murine and human prostate cancer cell lines, we generated a stress-induced model of dormancy in vitro and demonstrated that the phenotype could be sustained upon intrailiac artery delivery into the bone marrow microenvironment. RNA sequencing analysis revealed that the transcription factor positive regulatory domain–containing 16 ( PRDM16 ) was commonly upregulated in dormant prostate cancer cells compared with controls. Furthermore, bone marrow–disseminated prostate cancer cells from primary orthotopic tumors were largely positive for PRDM16. Genetic ablation and forced ectopic expression supported a role for PRDM16 in maintaining prostate cancer dormancy in vitro and in vivo . Clinically, PRDM16 negatively correlated with disease recurrence and with the E2F cell-cycle program in disseminated tumor cells derived from the bone marrow of patients with prostate cancer. Gene enrichment and characterization studies implicated PRDM16 as a regulator of metabolic and cell-cycle pathways. Chromatin immunoprecipitation–qPCR further revealed that PRDM16 binds upstream of the promoter of RB1 , a potent repressor of E2F activity. Overall, this study developed a straightforward method for inducing cancer cell dormancy and applied this approach to find that PRDM16 governs an intrinsic dormancy program in prostate cancer. Significance: PRDM16 initiates a dormancy program in prostate cancer cells that is sustained in the bone marrow microenvironment, highlighting PRDM16 as a potential biomarker for relapse and target for eliminating dormant cancer cells.

Year:

2026

Despite the availability of effective therapies such as proteasome inhibitors, multiple myeloma (MM) patients relapse with refractory disease. To identify new therapeutic targets, we assessed RNA sequencing data from CD138+ MM patient cells (n = 813) across disease stages and found that an autophagy gene signature, and particularly ULK3 expression, was strongly associated with disease progression. Functional studies revealed that ULK3 contributes to MM cell survival as part of the ULK-ATG13-FIP200 complex. We generated inhibitors (SG3-014/MA9-060) with nanomolar potency and confirmed their binding mode through co-crystallization with ULK3. In vivo, ULK3 inhibition reduced MM burden, improved survival, and protected against cancer-induced bone disease. MA9-060 also restored sensitivity to proteasome inhibitors in resistant MM cells. This synergy was validated ex vivo in patient samples, especially those with high ULK3 expression. These findings indicate a new role for ULK3-mediated autophagy in cancer and suggest that ULK3 inhibition is an effective treatment strategy for both newly diagnosed and refractory MM disease.

Year:

2025

Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow–resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. In this study, we present an integrated functional genomic analysis of tumor samples from patients multiple myeloma that were assessed for their ex vivo drug sensitivity to 37 drugs, clinical variables, cytogenetics, mutational profiles, and transcriptomes. This analysis revealed a multiple myeloma transcriptomic topology that generates “footprints” in association with ex vivo drug sensitivity that have both predictive and mechanistic applications. Validation of the transcriptomic footprints for the anti-CD38 mAb daratumumab (DARA) and the nuclear export inhibitor selinexor (SELI) demonstrated that these footprints can accurately classify clinical responses. The analysis further revealed that DARA and SELI have anticorrelated mechanisms of resistance, and treatment with a SELI-based regimen immediately after a DARA-containing regimen was associated with improved survival in three independent clinical trials, supporting an evolutionary-based strategy involving sequential therapy. These findings suggest that this unique repository and computational framework can be leveraged to inform underlying biology and to identify therapeutic strategies to improve treatment of multiple myeloma. Significance: Functional genomic analysis of primary multiple myeloma samples elucidated predictive biomarkers for drugs and molecular pathways mediating therapeutic response, which revealed a rationale for sequential therapy to maximize patient outcomes.

Year:

2025

Cancer-induced bone disease greatly diminishes the quality of life for patients with bone metastatic breast cancer, resulting in painful skeletal-related events including bone loss and fracture. Improved understanding of the roles of osteoblasts and osteoclasts, and how tumors alter their biology, has led to blockbuster therapies that significantly reduce skeletal-related events, but the disease remains incurable. However, emerging technologies and tools for studying the role of other stromal and immune components in controlling tumor–host interactions have begun to reveal new insights that may yield tractable therapeutic targets to further mitigate the painful effects of bone metastases. In this issue of Cancer Research, Kaur and colleagues study osteocytes, which are terminally differentiated osteoblasts and entombed within the bone matrix, from established bone metastatic breast cancer and report how the disease ages them as characterized by a senescence-associated secretory phenotype. This premature development of osteocyte senescence in turn enhances bone destruction and osteoclastogenic potential. Targeting senescent cells using senolytics suppressed bone resorption and preserved bone mass. Collectively, these findings underscore osteocyte involvement in the “vicious cycle” of bone metastasis, and targeting senescent osteocytes represents a new avenue for managing cancer-induced bone disease. See related article by Kaur et al., p. 3936

Year:

2024

Collaborators (9)

Niveditha Nerlakanti

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Lori A. Hazlehurst

West Virginia University

UNITED STATES
View details

Praneeth Reddy Sudalagunta

Applied Research Scientist II

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Eric Welsh

Senior Staff Scientist

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Oliver Hampton

Chief Data Officer

Southwest Research Institute

UNITED STATES
View details

Kenneth Shain

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Mostafa Nasr

Johns Hopkins University

UNITED STATES
View details

rachid baz

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Christopher Cubitt

Core Staff Scientist

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details